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COMMENT
Single-dose intraoperative radiotherapy during lumpectomy
for breast cancer: an innovative patient-centred treatment
Jayant S. Vaidya 1, Max Bulsara1,2, Michael Baum1, Jeffrey S. Tobias3 on behalf of the TARGIT-A trial authors
In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-
inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any
breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in
pre-operative consultations with eligible patients.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01233-5
MAIN
In 1996, the British Journal of Cancer published original work from
our group, describing widespread spatial distribution of additional
cancer foci in mastectomy specimens of patients who were
otherwise suitable for breast conservation.1 We proposed that
these foci may not be clinically relevant because of local
recurrence after breast conservation occurs mainly at the site of
primary tumour. The TARGIT-A randomised trial2 was firmly rooted
in this initial observation, and compared risk-adapted single-dose
targeted intraoperative radiotherapy (TARGIT-IORT) given during
lumpectomy vs conventional whole-breast external beam radio-
therapy (EBRT) in an international randomised non-inferiority trial.
The long-term results of the randomised TARGIT-A trial were
recently published.3 They confirmed comparable long-term
effectiveness of risk-adapted TARGIT-IORT and EBRT in terms of
breast cancer control. At 5-years complete follow-up, for the
primary outcome of absolute difference in raw local-recurrence
rates was 1.16% with the upper 90% confidence limit of 1.99%,
confirming non-inferiority at the prespecified margin of 2.5%. With
long-term follow-up (median 9 years, maximum 19 years), no
statistically significant difference was found in local or distant
control of breast cancer, breast-preservation or breast cancer
mortality. Deaths from causes other than breast cancer were
significantly fewer in the TARGIT-IORT arm—HR 0.59 (0.40–0.86)
P= 0.005, with 12-year rates being 5.41 vs 9.85%, a reduction
of 4.44%.
In this commentary we would like to address a number of
critical points.
(1) The first of these is to emphasise that TARGIT-A trial was not
restricted only to patients with a very low risk of local
recurrence. Participants had a much higher risk profile than
with other trials of partial breast irradiation (PBI, Table 13–11).
These other trials restricted the trial entry much more
stringently, only recruiting patients with the best prognostic
features. By contrast, a substantial absolute number of
patients in TARGIT-A, just like the Fast-Forward trial of
shorter-course whole breast radiotherapy (Table 2)12 were at
higher risk of relapse: 1898 (83%) were younger than 70 years,
366 (16%) had tumours >2 cm in size, 443 (20%) patients had
grade 3 cancers, 488 (22%) patients had involved nodes and
426 (19%) had ER- or PgR-negative tumours.
Similarly, patients in the three main trials comparing
radiotherapy vs no-radiotherapy (Table 2—CALBG, BASO-II
and PRIME-II),13–16 were again very highly selected for their
low-recurrence risk. By contrast with TARGIT-A, they were
strictly limited to those older than 65 or 70 years, with smaller,
lower grade, node negative and ER-positive tumours. Despite
this, the 5-year local-recurrence rates with ‘no-radiotherapy’
were 2–3 times higher than those seen with TARGIT-IORT
(Table 2).
For the record, most patients in the TARGIT-A trial who had
high-risk features did not receive supplemental EBRT after
TARGIT-IORT as part of the risk-adapted approach. For
example, supplemental EBRT was not given to 78% of Grade
3, not given to 82% of ER-negative and not given to 63% of
node-positive patients. Rather, the decision regarding use of
supplemental EBRT was made for the individual patient by the
treating multidisciplinary team, particularly bearing in mind
the main indications of unexpected lobular cancer and
positive margins. We regard this as a more patient-centred
approach, which takes account of the individual patient-
specific circumstances, including their preferences.
What does all this add up to? Data from the TARGIT-A trial
suggest that PBI using this risk-adapted TARGIT-IORT
approach is applicable to a breast cancer population more
widely inclusive than those recruited in other PBI or ‘no-
radiotherapy’ trials. By having TARGIT-IORT during their
lumpectomy, 8 out of 10 patients complete their radiotherapy
right away, and the benefits include avoiding repeated
hospital visits,17 a generally lower toxicity, and an improved
quality of life.18–23
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For NSABP-39 overall LR used for balloon. External beam days includes half a day for planning. The very old or small trials with less than 500 patients or those
with less than 5-year follow-up—from Leeds (EBRT over 28 days, n= 174, published 2005)38 and Christie (EBRT 10 days, n= 708, published 1995)39 both with
worse outcome for PBI, Budapest (interstitial wires twice a day over 7 days, n= 258, published 2013) with similar outcome for PBI40 and trials with no published
cancer outcome data41 are not included in this table. Table reproduced and slightly modified from Vaidya, J.S., Bulsara, M., Baum, M. et al. Intraoperative
radiotherapy for breast cancer: powerful evidence to change practice, Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00471-7 (2021).
Numbers are for patients with invasive breast cancer.
bkgr expected background risk in the control arm, ET endocrine therapy, QOL quality of life.
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(2) An important statistical point relates to the use of
Kaplan–Meier (K–M) curves. These are very informative if
properly computed. The first step for estimating the risk of any
event (e.g. local recurrence), is to categorise each patient into
either having the event or not. The time-to-event is then used
to plot a graph. This would work well if everyone’s follow-up
was the same and no one died, but this of course is never the
case because patients are never recruited all at the same
instant in any trial. The K–M model therefore uses a method
called ‘censoring’, which means that a patient’s data are used
until the point when they were last seen. The assumption is
that they are alive after they were last seen and continue to
have a risk of having local recurrence. But, sadly, some
patients die during follow-up, at which point this assumption
is of course no longer true. So, when plotting K–M estimates
for local recurrence, one should not categorise patients who
have died as ‘censored’. Such a plot must include death as an
event.3 Both the plot and any estimate in which the dead
have been censored are set in an imaginary world where
there is a continual risk of local recurrence after death.
Unfortunately, such graphs have frequently been published
and are inevitably misleading to readers.
Here is an example to make this clearer. Let’s look at the
NSABP-B39 data.24 Their K–M graph of local recurrence shows
that the chance of having local recurrence with PBI at 10 years
is 4.6%, therefore 95.4% of patients can be expected to be
local-recurrence free. This immediately leads to a paradox
because in fact, only 90.6% are alive at 10 years, so how can a
larger number of patients (95.4%) be around (alive) to be
local-recurrence free? A further example comes from the
CALGB trial,14 in which over 90% patients are estimated to be
alive without local recurrence at 10 years, when in fact only
60% are actually alive. Thus, such a K–M graph allegedly
depicting local control over time is misleading.
For this reason both DATECAN25 (European) and STEEP26
(American) guidelines, rightly insist that death and local
recurrence should both be included as clinical events for
assessing local treatments for breast cancer.
Most importantly of all, patients naturally need to know the
local control achieved by any new approach compared with
the previous standard, which is precisely provided by the
outcome of local-recurrence-free survival.
(3) Next, we would like to discuss the persistent finding of fewer
non-breast cancer deaths with TARGIT-IORT, compared with
whole-breast radiotherapy. The reduction was mainly due to
fewer deaths from cardiovascular or lung problems and from
other cancers and was not small in magnitude: 41% in relative
terms and 4.4% at 12 years in absolute terms.
Randomisation, especially when the trial size is large,
ensures that both known and unknown factors are well
balanced. In the TARGIT-A trial, all known prognostic factors3
were well balanced, as well as age and body mass index
(BMI),3 relevant for risks of cardiovascular27 and malignant
disease.28
This somewhat surprising observation is in fact consistent
with the results of meta-analyses of randomised trials
comparing partial breast irradiation with whole-breast irradia-
tion.29,30 It is well to remember that even modern
Table 2. Modern trials of no-radiotherapy, the trial of short course whole-breast radiotherapy and the TARGIT-A trial.
CALGB No RT
vs WBRT
BASO 2 No RT
vs WBRT




TARGIT-A trial risk-adapted single-
dose TARGIT-IORT vs WBRT
Number for comparison 636 1135 1326 2562 2298












T Size limits ≤2 cm ≤2 cm ≤3 cm T1–T3 ≤3.5 cm










LV invasion No info. Negative Neg if Gr 3 No restriction No restriction
ER status Positive Positive Positive No restriction No restriction
Additional hospital visits 1 1 1 7–15 None in 80% of cases; WBRT
recommended in 20%
5-year local-recurrence rates 4 vs 1% 6 vs 2% 4.1 vs 1.3%
Difference 2.9% (upper
95%CI 4.8%)

















10-yr LR 9.8% vs 0.9%.
Binomial 10-year
Non-breast cancer
deaths 3.9% vs 6.1%
and total deaths
13.2% vs 12%
Not available At median follow-up of 9 years (max
19 years):
No difference in local/distant
control/breast preservation/breast
cancer mortality
Significantly fewer deaths from




No No No Yes No
Mortality No difference No difference No difference No difference Significantly reduced non-BC
mortality with TARGIT-IORT
No difference in BC mortality
Toxicity in experimental arm Not reported Not reported Not reported Higher (e.g. breast induration/
hardness)
Reduced
Quality of life with
experimental treatment
Not reported Not reported Higher insomnia
No improvement in
QOL
Not reported Improved breast related QOL
Improved cosmetic outcome
Reduced pain
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radiotherapy increases cardiac and lung cancer mortality.31–35
This is particularly important in current or ex-smokers,31 in
which a survival decrement of 6% is estimated over a 30 year
period. This detriment is likely to outweigh any possible
survival benefit from radiotherapy for these patients with early
breast cancer.36
Perhaps even more important nowadays, in patients with
screen-detected cancer, where the dangers of overtreatment
are now so well recognised,37 we argue that it is both logical
and in the patient’s interest to use TARGIT-IORT, in order to
minimise side effects.
(4) Finally, it is obvious that this work has special relevance during
the current COVID-19 pandemic during which additional visits
for radiotherapy consultations, planning and treatment all
raise the risks to a vulnerable population as well as adding to
pressures on an overstretched hospital system. TARGIT-IORT
could help reduce these risks and save precious resources.
Conclusion
Using the approach of risk-adapted TARGIT-IORT in patients with
early breast cancer avoids the inconvenience and toxicity of
whole-breast radiotherapy in 8 out of every 10 patients. When
compared with whole-breast radiotherapy in the randomised
TARGIT-A trial, now with long-term follow up, no difference was
found for any breast cancer outcomes, but there was a reduction
in non-breast cancer mortality with TARGIT-IORT. Previous studies
have shown that the other advantages include reduced breast
pain, a better quality of life,18–23 a cosmetically superior outcome
and reduced travelling time for the patient.17
Clinicians and patients in 38 countries (260 centres) have been
adopting TARGIT-IORT since the publication of the first results, and
over 45,000 patients have been treated so far. We believe that the
long-term data,3 taken together with the many obvious benefits for
the patient, provide compelling evidence to roll this out further.
Finally, all doctors in the UK are now obliged to follow the
recently published GMC guidelines which underline the essential
nature of adequate patient information—i.e. what they can
reasonably expect to be told—in order to provide valid consent
(https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-
doctors/consent). This powerful principle is now fully enshrined in
UK law (Montgomery v Lanarkshire Health Board, 2015).
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